Microlyse; a thrombolytic agent that targets VWF for clearance of microvascular thrombosis

Steven de Maat, Chantal Clark, Arjan D Barendrecht, Simone Smits, Nadine D van Kleef, Hinde El Otmani, Manon Waning, Marc Vincent Adriaan van Moorsel, Michael Szardenings, Nicolas Delaroque, Kristof Vercruysse, Rolf T Urbanus, Silvie Sebastian, Peter J Lenting, Christoph Eugen Hagemeyer, Thomas Renné, Karen Vanhoorelbeke, Claudia Tersteeg, Coen Maas

Research output: Contribution to journalArticleAcademicpeer-review


Thrombotic microangiopathies are hallmarked by attacks of disseminated microvascular thrombosis. In thrombotic thrombocytopenic purpura (TTP), this is caused by a rise in thrombogenic ultra-large von Willebrand factor (VWF) multimers because of ADAMTS13 deficiency. We previously reported that systemic plasminogen activation is therapeutic in a TTP mouse model. In contrast to its natural activators (ie, tissue plasminogen activator and urokinase plasminogen activator [uPA]), plasminogen can directly bind to VWF. For optimal efficacy and safety, we aimed to focus and accelerate plasminogen activation at sites of microvascular occlusion. We here describe the development and characterization of Microlyse, a fusion protein consisting of a high-affinity V HH targeting the CT/CK domain of VWF and the protease domain of uPA, for localized plasminogen activation on microthrombi. Microlyse triggers targeted destruction of platelet-VWF complexes by plasmin on activated endothelial cells and in agglutination studies. At equal molar concentrations, Microlyse degrades microthrombi sevenfold more rapidly than blockade of platelet-VWF interactions with a bivalent humanized V HH (caplacizumab*). Finally, Microlyse attenuates thrombocytopenia and tissue damage (reflected by increased plasma lactate dehydrogenase activity, as well as PAI-1 and fibrinogen levels) more efficiently than caplacizumab* in an ADAMTS13 −/− mouse model of TTP, without affecting hemostasis in a tail-clip bleeding model. These findings show that targeted thrombolysis of VWF by Microlyse is an effective strategy for the treatment of TTP and might hold value for other forms of VWF-driven thrombotic disease.

Original languageEnglish
Pages (from-to)597-607
Number of pages11
Issue number4
Early online date9 Nov 2021
Publication statusPublished - 27 Jan 2022


Dive into the research topics of 'Microlyse; a thrombolytic agent that targets VWF for clearance of microvascular thrombosis'. Together they form a unique fingerprint.

Cite this